<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and Dabrafenib (D). (E) The binding modes of the BRAF inhibitors in the first binding site (monomer A). PLX4720 (in green), Vemurafenib (in red), PLX7904 (in blue), and Dabrafenib (in cyan). (F) The binding modes of the BRAF inhibitors in the second binding sites (monomer B). Among studied inhibitors, only PLX4720 (in green) and Dabrafenib (in cyan) bind to the second monomer. Note structural similarity of the inhibitor binding mode and DFG-in/αC-out kinase conformation in the first monomer, while alternative inhibitor binding modes and conformational variability in the second monomer.</p
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
<p><b>(A)</b> BBR-7/BRAF interactions; <b>(B)</b> Vemurafenib/BRAF interactions. Lys483 formed H-bon...
Recently we reported two new structural scaffolds as potential inhibitors of BRAF; both series of com...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
<p>Binding free energies and alanine scanning of the binding site residues in the drug-bound monomer...
<p>Conformational dynamics profiles of the BRAF dimer complexes with PLX4720 (pdb id 3C4C) (A), Dabr...
<p>Dabrafenib chemical structure (A). Dabrafenib potency (IC<sub>50</sub>) was measured against the ...
The success of the first approved kinase inhibitor imatinib has spurred great interest in the develo...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that sends a sig...
The oncogenic mutated kinase BRAFV600E is an attractive molecular target because it is expressed in ...
We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mut...
Hsin-Chieh Tang,1 Yu-Chian Chen1–3 1Department of Biomedical Informatics, Asia University, Ta...
We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A...
The BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
<p><b>(A)</b> BBR-7/BRAF interactions; <b>(B)</b> Vemurafenib/BRAF interactions. Lys483 formed H-bon...
Recently we reported two new structural scaffolds as potential inhibitors of BRAF; both series of com...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
<p>Binding free energies and alanine scanning of the binding site residues in the drug-bound monomer...
<p>Conformational dynamics profiles of the BRAF dimer complexes with PLX4720 (pdb id 3C4C) (A), Dabr...
<p>Dabrafenib chemical structure (A). Dabrafenib potency (IC<sub>50</sub>) was measured against the ...
The success of the first approved kinase inhibitor imatinib has spurred great interest in the develo...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that sends a sig...
The oncogenic mutated kinase BRAFV600E is an attractive molecular target because it is expressed in ...
We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mut...
Hsin-Chieh Tang,1 Yu-Chian Chen1–3 1Department of Biomedical Informatics, Asia University, Ta...
We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A...
The BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
<p><b>(A)</b> BBR-7/BRAF interactions; <b>(B)</b> Vemurafenib/BRAF interactions. Lys483 formed H-bon...
Recently we reported two new structural scaffolds as potential inhibitors of BRAF; both series of com...